艾美疫苗(06660.HK)建議採納股份獎勵計劃
格隆匯4月17日丨艾美疫苗(06660.HK)公吿,為推動公司業務發展及加快建議A股上市申請進度,公司董事會建議採納集團關鍵崗位核心人員的股份獎勵計劃。目前預期根據建議股份獎勵計劃授出的所有獎勵及╱或期權所涉及的公司股份總數將不超過採納股份獎勵計劃當日已發行股份總數的5%。股份獎勵計劃項下的獎勵可採取H股及內資股的股份期權或受限制股份形式。根據股份獎勵計劃授出的獎勵或期權的授出價或行使價,預期將參考相關時間的股份市價釐定。
董事會授權董事會主席根據第三方專業顧問的意見釐定股份獎勵計劃的條款。股份獎勵計劃的條款須提交董事會審閲及批准。採納股份獎勵計劃須經公司股東於股東大會上批准。公司將召開股東大會以尋求股東批准採納股份獎勵計劃。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.